TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy CB Rodell, SP Arlauckas, MF Cuccarese, CS Garris, R Li, MS Ahmed, ... Nature biomedical engineering 2 (8), 578-588, 2018 | 941 | 2018 |
Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ... Immunity 49 (6), 1148-1161. e7, 2018 | 918 | 2018 |
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy SP Arlauckas, CS Garris, RH Kohler, M Kitaoka, MF Cuccarese, KS Yang, ... Science translational medicine 9 (389), eaal3604, 2017 | 655 | 2017 |
IRF3 and type I interferons fuel a fatal response to myocardial infarction KR King, AD Aguirre, YX Ye, Y Sun, JD Roh, RP Ng Jr, RH Kohler, ... Nature medicine 23 (12), 1481-1487, 2017 | 504 | 2017 |
Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages SP Arlauckas, SB Garren, CS Garris, RH Kohler, J Oh, MJ Pittet, ... Theranostics 8 (21), 5842, 2018 | 299 | 2018 |
Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma AP Algazi, CG Twitty, KK Tsai, M Le, R Pierce, E Browning, R Hermiz, ... Clinical Cancer Research 26 (12), 2827-2837, 2020 | 136 | 2020 |
Choline kinase alpha—Putting the ChoK-hold on tumor metabolism SP Arlauckas, AV Popov, EJ Delikatny Progress in Lipid Research 63, 28-40, 2016 | 79 | 2016 |
Prediction of anti-cancer nanotherapy efficacy by imaging MA Miller, S Arlauckas, R Weissleder Nanotheranostics 1 (3), 296, 2017 | 77 | 2017 |
Recording the wild lives of immune cells MJ Pittet, CS Garris, SP Arlauckas, R Weissleder Science immunology 3 (27), eaaq0491, 2018 | 75 | 2018 |
Quantification of tumor fluorescence during intraoperative optical cancer imaging RP Judy, JJ Keating, EM DeJesus, JX Jiang, OT Okusanya, S Nie, ... Scientific reports 5 (1), 16208, 2015 | 55 | 2015 |
Magnetic resonance spectroscopy for detection of choline kinase inhibition in the treatment of brain tumors M Kumar, SP Arlauckas, S Saksena, G Verma, R Ittyerah, S Pickup, ... Molecular cancer therapeutics 14 (4), 899-908, 2015 | 54 | 2015 |
Direct inhibition of choline kinase by a near-infrared fluorescent carbocyanine SP Arlauckas, AV Popov, EJ Delikatny Molecular cancer therapeutics 13 (9), 2149-2158, 2014 | 37 | 2014 |
Near infrared fluorescent imaging of choline kinase alpha expression and inhibition in breast tumors SP Arlauckas, M Kumar, AV Popov, H Poptani, EJ Delikatny Oncotarget 8 (10), 16518, 2017 | 33 | 2017 |
LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects HW Liao, C Garris, C Pfirschke, S Rickelt, S Arlauckas, M Siwicki, ... Cell Stress 3 (11), 348, 2019 | 26 | 2019 |
Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ... Immunity 55 (9), 1749, 2022 | 24 | 2022 |
Imaging of cancer lipid metabolism in response to therapy SP Arlauckas, EA Browning, H Poptani, EJ Delikatny NMR in Biomedicine 32 (10), e4070, 2019 | 11 | 2019 |
Macrophage imaging and subset analysis using single-cell RNA sequencing S Arlauckas, N Oh, R Li, R Weissleder, MA Miller Nanotheranostics 5 (1), 36, 2021 | 9 | 2021 |
Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing TF Hill, P Narvekar, GD Asher, JN Edelstein, ND Camp, A Grimm, ... Molecular Therapy 32 (8), 2676-2691, 2024 | 5 | 2024 |
In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model DJ Young, AJ Edwards, KGQ Caceda, E Liberzon, J Barrientos, SG Hong, ... Molecular Therapy 33 (2), 580-594, 2025 | 1 | 2025 |
CRISPR/Cas9-Based Precision B Cell Gene Engineering Coupled with Artificial Intelligence-Guided Protein Design Produces Active Tissue Nonspecific Alkaline Phosphatase for the … M Musial-Siwek, S Leach, W Bainter, M Clements, S Singh, T Mullen, ... ASBMR 2024 Annual Meeting, 2024 | 1 | 2024 |